ForDoz Pharma to manufacture LipoMedix’ oncology candidate Promitil
New Jersey-based ForDoz Pharma has signed an agreement with LipoMedix for manufacturing the latter’s lead compound – pegylated liposomal Promitil (PL-MLP) for a phase 2 clinical trial. According to ForDoz Pharma, the liposomal formulation of Promitil is designed for selectively delivering the therapeutic agent to tissues affected by cancer and is suited ideally for cancer […]